Business Name: |
Zhou Lingxiang MD |
Contact Person: |
Lingxiang Zhou |
Address: |
330 Laurel St # 2100, Des Moines, Iowa 50314 |
Phone Number: |
(515) 643-8611 |
Annual Revenue (USD): |
$100.000 to $499.999 |
Founding Year: |
2001 |
Location Type: |
Single Location |
Employee Number: |
1 to 4 |
Business Type: |
B2C (Business to Consumer) |
Business Category: |
Doctors |
SIC Code: |
8011 |
NAICS Code: |
6211110 |
Share This Business: |
|
Related Businesses: |
Napa Balasubrama MD - Des Moines, IA 50314 Schultheis Kenneth P MD - Des Moines, IA 50314 Bhavsar Vipin MD - Des Moines, IA 50314 Vijaya L Dhanwada Md - Des Moines, IA 50314 Mr James Puiien Md - Des Moines, IA 50314 Massop Douglas MD - Des Moines, IA 50314 Mahoney Craig R MD - Des Moines, IA 50314 Mark A Tannenbaum Dr - Des Moines, IA 50314 Khoo Teck MD - Des Moines, IA 50314 Galiota Nicholas J MD - Des Moines, IA 50314 Cutler Keven MD - Des Moines, IA 50314 Brown George W MD - Des Moines, IA 50314 Mercy Wound Treatment Center - Des Moines, IA 50314 Metts Michael J DO - Des Moines, IA 50314 Torstenson Tiffany A DO - Des Moines, IA 50314 Sandre Angela E DO - Des Moines, IA 50314 Mc Clairen Jr Willie C MD - Des Moines, IA 50314 Mercy Clinics Inc Admin - Des Moines, IA 50314 Simon Dana MD - Des Moines, IA 50314 Primary Health Care Inc - Des Moines, IA 50314 |
The company Zhou Lingxiang MD provides B2C services in the form of Doctors from its single location in Iowa.
1 to 4 employees work for Zhou Lingxiang MD, and the business now earns $100.000 to $499.999 per annum.
Zhou Lingxiang MD was launched in 2001 and is classified under SIC code and category 8011 , and NAICS number and grouping 6211110 .
To contact Zhou Lingxiang MD, please call Lingxiang Zhou with the phone number (515) 643-8611 or visit its single location at 330 Laurel St # 2100 in Des Moines, Iowa 50314.
The location of the single location can also be found using the coordinates 41.59734,-93.62222.
Read more details about this business on the webpage or follow the company’s social media accounts, on Twitter and on Facebook.